Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 21.12.2021
Cogia AG
Dynamic growth with patented semantic solutions in the area of 'Big Data
Analytics'
Cogia AG is a full-service provider of AI-based, patented, semantic
solutions and services in the field of 'Big Data Analytics', with a focus
on customer experience, monitoring and engagement. Cogia's goal is to
support its customers, whether companies, associati [ … ]
Mon, 13.12.2021
Aspermont Limited
Preliminary FY2021 shows positive Net Profit After Tax
FY2021 preliminary report shows continued growth
As per their preliminary numbers, the company has delivered on all their
guidance:
- Overall growth
- Subscriptions growth rate to go back to pre-Covid-19 levels
- Growth in audience
- High growth in new products
- Continue [ … ]
Fri, 10.12.2021
HAEMATO AG
In operational terms, HAEMATO AG is heading for a record year following the
acquisition of M1 Aesthetics GmbH. In addition, the expansion of their
private label business is increasingly coming into focus. In this regard,
the company plans to expand its portfolio with a botulinum toxin product
under its own brand. GBC analyst Cosmin Filker spoke wi [ … ]
Thu, 09.12.2021
EasyMotionSkin Tec AG
Successful listing of EasyMotionSkin Tec AG on the m:access of the Munich
Stock Exchange
On 09.12.2021 EasyMotionSkin Tec AG was successfully listed on the m:access
of the Munich Stock Exchange. The initial share price is 14.50 EUR.
According to the management, no extensive capital market transactions are
planned in the near future.
The EasyMo [ … ]
Mon, 06.12.2021
Defence Therapeutics Inc.
'We can work on any disease and adapt to any emergent pandemic such as the
one related to SARS-CoV2'
In its current letter to shareholders, Defence Therapeutics reports the
successful completion of its protein-based COVID vaccine (AccuVAC-PT001)
toxicology studies in non-rodent rabbit model. The AccuVAC-PT001 vaccine is
an injectable vaccine cap [ … ]
Mon, 22.11.2021
IGEA Pharma N.V.
Reverse IPO of Blue Sky Natural Resources in IGEA Pharma. Realignment to
CBD extraction. Aggressive growth expected with strong scaling effects.
Blue Sky Natural Resources Ltd. (Blue Sky) was contributed to IGEA Pharma
N.V. (IGEA Pharma) on 27 September 2021 via a capital increase in kind. The
business model is now to change fundamentally. The w [ … ]
Mon, 22.11.2021
Aspermont Limited
Impressive revenue growth and notable raise in gross profit
Aspermont's performance demonstrates the company's ability to grow at a
fast rate. When compared to Q4-2020, the company's revenues increased in
all sectors in Q4-2021. Currently, we can only look at partial numbers due
to Australian stock market regulatory laws.
These figures show a [ … ]
Tue, 16.11.2021
Cardiol Therapeutics
GBC AG to present an investor round table conference call with Cardiol
Therapeutics and will present latest development.
With the completion of the Public Offering, the company will have raised
more than $ 52.4 million in cash. Included is $ 2.4 million from the
warrants' accelerated expiration date of June 4, 2020. On November 2nd, the
company [ … ]
Mon, 15.11.2021
MagForce AG
1st HY 2021: FDA approval for final pivotal study received, forecasts and
price target confirmed, rating: BUY
In the context of the research study (Anno) of 20.07.2021, we had already
postulated our expectations that MagForce AG would probably report low
treatment figures overall in Europe (indication area: glioblastoma) in the
first half of 202 [ … ]
Thu, 11.11.2021
CENIT AG
9M 2021: Constant revenue development, noticeable improvement in earnings;
forecasts and target price confirmed; rating: BUY
From the perspective of the first nine months of 2021, CENIT AG achieved an
overall constant sales development with a slight decline in sales of -0.4%.
After the first quarter was still strongly affected by the pandemic
co [ … ]